TriSalus Life Sciences Inc. (TLSI)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
TriSalus Life Sciences Q1 Earnings Call Highlights
TriSalus Life Sciences NASDAQ: TLSI reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device.
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates
TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.33 per share a year ago.
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JC Joseph Castro Nuveen LLC | 36,550 | $223,609.88 | $133,042 | -$90,567.88 | -40.5% |
| JR John Ritter Ritter Daniher Financial Advisory LLC / DE | 500 | $3,490 | $1,825 | -$1,665 | -47.71% |
 Alexandra Stickelman Root Financial Partners, LLC | 12 | $48 | $43.68 | -$4.32 | -9% |
 Ashley Meredith Abel Hall, LLC | 10,500 | $73,290 | $38,220 | -$35,070 | -47.85% |
| MS Mark Schafer Police & Firemen's Retirement System of New Jersey | 5,400 | $29,430 | $19,656 | -$9,774 | -33.21% |
TriSalus Life Sciences Inc. (TLSI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has TriSalus Life Sciences Inc. ever had a stock split?
TriSalus Life Sciences Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Mary T. Szela CEO | NASDAQ (NMS) Exchange | 89680M101 CUSIP |
| US Country | 110 Employees | - Last Dividend | - Last Split | 10 Aug 2023 IPO Date |
Overview
TriSalus Life Sciences, Inc. is a pioneering medical technology company specialized in advancing drug delivery technologies and developing innovative immune-oncology therapeutics, particularly focusing on the treatment of liver and pancreatic cancers. Established in 2009 and based in Westminster, Colorado, the company has been at the forefront of integrating sophisticated drug delivery systems with cutting-edge therapeutic approaches to offer better treatment options for patients suffering from these challenging cancers. TriSalus aims to address the critical need for more effective treatment modalities by leveraging its proprietary technologies and conducting rigorous clinical trials to bring groundbreaking solutions to the medical community and patients alike.
Products and Services
- Pressure Enabled Drug Delivery (PEDD) Infusion Systems
Among TriSalus' innovative offerings is the TriNav infusion system, specifically designed to enhance the efficacy of transarterial radioembolization (TARE) and chemoembolization procedures. These are critical treatments for patients with liver cancer and metastatic diseases. The unique technology behind the TriNav system allows for precise and controlled delivery of therapeutic agents directly to the tumor site, potentially improving outcomes by maximizing drug concentration in the targeted area while minimizing systemic exposure.
- Pancreatic Retrograde Venous Infusion Device
This cutting-edge device is currently in Phase 1 clinical trials and represents a novel approach to treat locally advanced pancreatic cancer. By facilitating targeted delivery of therapeutic agents directly to the pancreas through the venous system, this device aims to significantly improve treatment penetration and efficacy for one of the most aggressive and difficult-to-treat forms of cancer.
- Nelitolimod - An Investigational Immunotherapeutic
TriSalus is also developing nelitolimod, an innovative immunotherapy currently in Phase 1 clinical trials. This investigational treatment is designed to combat a range of cancers, including uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. Nelitolimod exemplifies the company’s commitment to expanding the horizons of immune-oncology through novel therapeutic options that aim to improve patient outcomes significantly.
TriSalus Life Sciences serves a broad spectrum of healthcare professionals and patients, including interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company's dedicated sales representatives and managers are committed to providing exceptional service and support, ensuring that its innovative products and services are accessible to those in need.
